Literature DB >> 32369445

Impaired angiogenesis and extracellular matrix metabolism in autosomal-dominant hyper-IgE syndrome.

Natalia I Dmitrieva1, Avram D Walts1, Dai Phuong Nguyen1, Alex Grubb1, Xue Zhang2, Xujing Wang2, Xianfeng Ping1, Hui Jin1, Zhen Yu1, Zu-Xi Yu3, Dan Yang1, Robin Schwartzbeck1, Clifton L Dalgard4,5,6, Beth A Kozel7, Mark D Levin7, Russell H Knutsen7, Delong Liu7, Joshua D Milner8, Diego B López8, Michael P O'Connell8, Chyi-Chia Richard Lee9, Ian A Myles10, Amy P Hsu10, Alexandra F Freeman10, Steven M Holland10, Guibin Chen1, Manfred Boehm1.   

Abstract

There are more than 7000 described rare diseases, most lacking specific treatment. Autosomal-dominant hyper-IgE syndrome (AD-HIES, also known as Job's syndrome) is caused by mutations in STAT3. These patients present with immunodeficiency accompanied by severe nonimmunological features, including skeletal, connective tissue, and vascular abnormalities, poor postinfection lung healing, and subsequent pulmonary failure. No specific therapies are available for these abnormalities. Here, we investigated underlying mechanisms in order to identify therapeutic targets. Histological analysis of skin wounds demonstrated delayed granulation tissue formation and vascularization during skin-wound healing in AD-HIES patients. Global gene expression analysis in AD-HIES patient skin fibroblasts identified deficiencies in a STAT3-controlled transcriptional network regulating extracellular matrix (ECM) remodeling and angiogenesis, with hypoxia-inducible factor 1α (HIF-1α) being a major contributor. Consistent with this, histological analysis of skin wounds and coronary arteries from AD-HIES patients showed decreased HIF-1α expression and revealed abnormal organization of the ECM and altered formation of the coronary vasa vasorum. Disease modeling using cell culture and mouse models of angiogenesis and wound healing confirmed these predicted deficiencies and demonstrated therapeutic benefit of HIF-1α-stabilizing drugs. The study provides mechanistic insights into AD-HIES pathophysiology and suggests potential treatment options for this rare disease.

Entities:  

Keywords:  Cardiovascular disease; Extracellular matrix; Monogenic diseases; Therapeutics; Vascular Biology

Mesh:

Substances:

Year:  2020        PMID: 32369445      PMCID: PMC7410079          DOI: 10.1172/JCI135490

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  71 in total

Review 1.  Revisiting STAT3 signalling in cancer: new and unexpected biological functions.

Authors:  Hua Yu; Heehyoung Lee; Andreas Herrmann; Ralf Buettner; Richard Jove
Journal:  Nat Rev Cancer       Date:  2014-11       Impact factor: 60.716

2.  Addressing challenges in the diagnosis and treatment of rare genetic diseases.

Authors:  Kym M Boycott; Diego Ardigó
Journal:  Nat Rev Drug Discov       Date:  2017-12-15       Impact factor: 84.694

3.  Frequent and widespread vascular abnormalities in human signal transducer and activator of transcription 3 deficiency.

Authors:  Marie-Olivia Chandesris; Arshid Azarine; Kim-Thanh Ong; Soraya Taleb; Pierre Boutouyrie; Elie Mousseaux; Mélissa Romain; Erwan Bozec; Stéphane Laurent; Nathalie Boddaert; Caroline Thumerelle; Isabelle Tillie-Leblond; Cyrille Hoarau; Yvon Lebranchu; Nathalie Aladjidi; François Tron; Vincent Barlogis; Gérard Body; Marine Munzer; Roland Jaussaud; Felipe Suarez; Olivier Clément; Olivier Hermine; Alain Tedgui; Olivier Lortholary; Capucine Picard; Ziad Mallat; Alain Fischer
Journal:  Circ Cardiovasc Genet       Date:  2011-11-14

Review 4.  Targeting hypoxia signalling for the treatment of ischaemic and inflammatory diseases.

Authors:  Holger K Eltzschig; Donna L Bratton; Sean P Colgan
Journal:  Nat Rev Drug Discov       Date:  2014-11       Impact factor: 84.694

Review 5.  HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond.

Authors:  Patrick H Maxwell; Kai-Uwe Eckardt
Journal:  Nat Rev Nephrol       Date:  2015-12-14       Impact factor: 28.314

6.  The Potential and Limits of Hematopoietic Stem Cell Transplantation for the Treatment of Autosomal Dominant Hyper-IgE Syndrome.

Authors:  Masakatsu Yanagimachi; Takashi Ohya; Tomoko Yokosuka; Ryosuke Kajiwara; Fumiko Tanaka; Hiroaki Goto; Takehiro Takashima; Tomohiro Morio; Shumpei Yokota
Journal:  J Clin Immunol       Date:  2016-04-18       Impact factor: 8.317

7.  Toll-like receptor stimulation induces higher TNF-alpha secretion in peripheral blood mononuclear cells from patients with hyper IgE syndrome.

Authors:  Mehdi Yeganeh; Philipp Henneke; Nima Rezaei; Stephan Ehl; Doerte Thiel; Nuria Matamoros; Cristina Pietrogrande; Teresa Espanol; Jiri Litzman; Jose L Franco; Ozden Sanal; Sara S Kilic; Anna Breborowicz; Alessandro Plebani; Ellen Renner; Simon Rothenfusser; Thomas R Hawn; Cristina Woellner; Bodo Grimbacher
Journal:  Int Arch Allergy Immunol       Date:  2008-02-11       Impact factor: 2.749

Review 8.  An Emerging Treatment Alternative for Anemia in Chronic Kidney Disease Patients: A Review of Daprodustat.

Authors:  Kimberly A Becker; John J Jones
Journal:  Adv Ther       Date:  2017-12-28       Impact factor: 3.845

9.  Generation of human induced pluripotent stem cell lines (NIHTVBi011-A, NIHTVBi012-A, NIHTVBi013-A) from autosomal dominant Hyper IgE syndrome (AD-HIES) patients carrying STAT3 mutation.

Authors:  Hui Jin; Zhen Yu; Keron Navarengom; Yangtengyu Liu; Natalia Dmitrieva; Amy P Hsu; Robin Schwartzbeck; Cornelia Cudrici; Elisa A Ferrante; Dan Yang; Steven M Holland; Alexandra F Freeman; Manfred Boehm; Guibin Chen
Journal:  Stem Cell Res       Date:  2019-10-17       Impact factor: 2.020

Review 10.  Pathogenesis of hyper IgE syndrome.

Authors:  Jennifer Heimall; Alexandra Freeman; Steven M Holland
Journal:  Clin Rev Allergy Immunol       Date:  2010-02       Impact factor: 10.817

View more
  7 in total

1.  Recurrent Breast Abscesses in a Female with Autosomal Dominant Hyper-IgE Syndrome.

Authors:  Vibha Szafron; Sohail R Shah; Galit Holzmann-Pazgal; Giancarlo Toledanes; Nicholas L Rider
Journal:  J Clin Immunol       Date:  2022-03-15       Impact factor: 8.542

Review 2.  STAT3 Hyper-IgE Syndrome-an Update and Unanswered Questions.

Authors:  Christo Tsilifis; Alexandra F Freeman; Andrew R Gennery
Journal:  J Clin Immunol       Date:  2021-05-01       Impact factor: 8.317

Review 3.  Tumor Necrosis Factor Receptors: Pleiotropic Signaling Complexes and Their Differential Effects.

Authors:  Portia Gough; Ian A Myles
Journal:  Front Immunol       Date:  2020-11-25       Impact factor: 7.561

4.  Differential responses to folic acid in an established keloid fibroblast cell line are mediated by JAK1/2 and STAT3.

Authors:  Katelyn J McCann; Manoj Yadav; Mohammadali E Alishahedani; Alexandra F Freeman; Ian A Myles
Journal:  PLoS One       Date:  2021-03-04       Impact factor: 3.240

Review 5.  Development of vascular disease models to explore disease causation and pathomechanisms of rare vascular diseases.

Authors:  Rebecca L Harper; Elisa A Ferrante; Manfred Boehm
Journal:  Semin Immunopathol       Date:  2022-03-01       Impact factor: 11.759

6.  STAT3 is critical for skeletal development and bone homeostasis by regulating osteogenesis.

Authors:  Siru Zhou; Qinggang Dai; Xiangru Huang; Anting Jin; Yiling Yang; Xinyi Gong; Hongyuan Xu; Xin Gao; Lingyong Jiang
Journal:  Nat Commun       Date:  2021-11-25       Impact factor: 14.919

7.  A comprehensive and universal approach for embryo testing in patients with different genetic disorders.

Authors:  Shuo Zhang; Caixia Lei; Junping Wu; Min Xiao; Jing Zhou; Saijuan Zhu; Jing Fu; Daru Lu; Xiaoxi Sun; Congjian Xu
Journal:  Clin Transl Med       Date:  2021-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.